An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology

被引:44
|
作者
Gingell, Joseph J. [1 ,2 ]
Simms, John [3 ]
Barwell, James [3 ]
Poyner, David R. [3 ]
Watkins, Harriet A. [1 ,2 ]
Pioszak, Augen A. [4 ]
Sexton, Patrick M. [5 ,6 ]
Hay, Debbie L. [1 ,2 ]
机构
[1] Univ Auckland, Sch Biol Sci, Auckland, New Zealand
[2] Univ Auckland, Maurice Wilkins Ctr Mol Biodiscovery, Auckland, New Zealand
[3] Aston Univ, Sch Life & Hlth Sci, Birmingham, W Midlands, England
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA
[5] Monash Univ, Monash Inst Pharmaceut Sci, Drug Discovery Biol, Parkville, Vic, Australia
[6] Monash Univ, Monash Inst Pharmaceut Sci, Dept Pharmacol, Parkville, Vic, Australia
基金
英国医学研究理事会; 英国惠康基金;
关键词
Amylin; accessory protein; CGRP; G protein-coupled receptor; RAMP; CALCITONIN-RECEPTOR; STRUCTURAL INSIGHTS; CRYSTAL-STRUCTURE; DIFFERENTIALLY MODULATE; COUPLED RECEPTORS; CGRP-RECEPTOR; AMYLIN; TERMINUS; RAMPS; RECOGNITION;
D O I
10.1038/celldisc.2016.12
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
G protein-coupled receptors are allosteric proteins that control transmission of external signals to regulate cellular response. Although agonist binding promotes canonical G protein signalling transmitted through conformational changes, G protein-coupled receptors also interact with other proteins. These include other G protein-coupled receptors, other receptors and channels, regulatory proteins and receptor-modifying proteins, notably receptor activity-modifying proteins (RAMPs). RAMPs have at least 11 G protein-coupled receptor partners, including many class B G protein-coupled receptors. Prototypic is the calcitonin receptor, with altered ligand specificity when co-expressed with RAMPs. To gain molecular insight into the consequences of this protein-protein interaction, we combined molecular modelling with mutagenesis of the calcitonin receptor extracellular domain, assessed in ligand binding and functional assays. Although some calcitonin receptor residues are universally important for peptide interactions (calcitonin, amylin and calcitonin gene-related peptide) in calcitonin receptor alone or with receptor activity-modifying protein, others have RAMP-dependent effects, whereby mutations decreased amylin/calcitonin gene-related peptide potency substantially only when RAMP was present. Remarkably, the key residues were completely conserved between calcitonin receptor and AMY receptors, and between subtypes of AMY receptor that have different ligand preferences. Mutations at the interface between calcitonin receptor and RAMP affected ligand pharmacology in a RAMP-dependent manner, suggesting that RAMP may allosterically influence the calcitonin receptor conformation. Supporting this, molecular dynamics simulations suggested that the calcitonin receptor extracellular N-terminal domain is more flexible in the presence of receptor activity-modifying protein 1. Thus, RAMPs may act in an allosteric manner to generate a spectrum of unique calcitonin receptor conformational states, explaining the pharmacological preferences of calcitonin receptor-RAMP complexes. This provides novel insight into our understanding of G protein-coupled receptor-protein interaction that is likely broadly applicable for this receptor class.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles
    Hay, Debbie L.
    Pioszak, Augen A.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56, 2016, 56 : 469 - 487
  • [2] Receptor activity-modifying proteins; multifunctional G protein-coupled receptor accessory proteins
    Hay, Debbie L.
    Walker, Christopher S.
    Gingell, Joseph J.
    Ladds, Graham
    Reynolds, Christopher A.
    Poyner, David R.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2016, 44 : 568 - 573
  • [3] The role of receptor activity-modifying proteins in obesity and diabetes mellitus
    Malcharek, Milena A.
    Pearce, Abigail
    Brighton, Cheryl A.
    Hornigold, David C.
    Ladds, Graham
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2024, 73 (04)
  • [4] Structure-function relationships of the N-terminus of receptor activity-modifying proteins
    Qi, Tao
    Hay, Debbie L.
    BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (05) : 1059 - 1068
  • [5] Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2)
    Weston, Cathryn
    Lu, Jing
    Li, Naichang
    Barkan, Kerry
    Richards, Gareth O.
    Roberts, David J.
    Skerry, Timothy M.
    Poyner, David
    Pardamwar, Meenakshi
    Reynolds, Christopher A.
    Dowell, Simon J.
    Willars, Gary B.
    Ladds, Graham
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (38) : 23009 - 23022
  • [6] Calcitonin and Amylin Receptor Peptide Interaction Mechanisms INSIGHTS INTO PEPTIDE-BINDING MODES AND ALLOSTERIC MODULATION OF THE CALCITONIN RECEPTOR BY RECEPTOR ACTIVITY-MODIFYING PROTEINS
    Lee, Sang-Min
    Hay, Debbie L.
    Pioszak, Augen A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (16) : 8686 - 8700
  • [7] Functional characterization of two human receptor activity-modifying protein 3 variants
    Bailey, Richard J.
    Bradley, Joshua W. I.
    Poyner, David R.
    Rathbone, Dan L.
    Hay, Debbie L.
    PEPTIDES, 2010, 31 (04) : 579 - 584
  • [8] Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins
    Kotliar, Ilana B.
    Lorenzen, Emily
    Schwenk, Jochen M.
    Hay, Debbie L.
    Sakmar, Thomas P.
    PHARMACOLOGICAL REVIEWS, 2023, 75 (01) : 1 - 34
  • [9] Receptor activity modifying proteins
    Sexton, PM
    Albiston, A
    Morfis, M
    Tilakaratne, N
    CELLULAR SIGNALLING, 2001, 13 (02) : 73 - 83
  • [10] Multiplexed mapping of the interactome of GPCRs with receptor activity-modifying proteins
    Kotliar, Ilana B.
    Bendes, Annika
    Dahl, Leo
    Chen, Yuanhuang
    Saarinen, Marcus
    Ceraudo, Emilie
    Dodig-Crnkovic, Tea
    Uhlen, Mathias
    Svenningsson, Per
    Schwenk, Jochen M.
    Sakmar, Thomas P.
    SCIENCE ADVANCES, 2024, 10 (31):